Generated by AI
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its current programs target rare, monogenic disorders of the central nervous system, with lead efforts centered on elevating progranulin levels and addressing underlying disease biology. The company’s pipeline includes clinical and early-stage candidates for conditions such as frontotemporal dementia, GM1 gangliosidosis, Krabbe disease, and other severe neurological disorders with limited treatment options. Passage Bio Inc. works in gene delivery and translational research to advance therapies designed for precise genetic correction or replacement within the brain and nervous system. Headquartered in Philadelphia, Pennsylvania, the company operates as a focused biotechnology developer within the genetic medicines field.
WebsiteOne Commerce Square
Philadelphia, PA, 19103
United States
Summary of Jun 25's posts. Generated by AI.
No summary yet.
Summary of Mar 31's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Investors talking about PASG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.